Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Cash from Investing Activities (2016 - 2025)

Immucell (ICCC) has disclosed Cash from Investing Activities for 16 consecutive years, with -$592024.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 569.62% year-over-year to -$592024.0, compared with a TTM value of -$1.2 million through Sep 2025, down 437.66%, and an annual FY2024 reading of -$461225.0, up 75.6% over the prior year.
  • Cash from Investing Activities was -$592024.0 for Q3 2025 at Immucell, down from -$125927.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $656684.0 in Q1 2021 and bottomed at -$1.5 million in Q4 2022.
  • Average Cash from Investing Activities over 5 years is -$471573.6, with a median of -$592024.0 recorded in 2025.
  • The sharpest move saw Cash from Investing Activities soared 102.27% in 2023, then tumbled 680.81% in 2024.
  • Year by year, Cash from Investing Activities stood at -$703279.0 in 2021, then tumbled by 111.89% to -$1.5 million in 2022, then skyrocketed by 102.27% to $33783.0 in 2023, then crashed by 680.81% to -$196216.0 in 2024, then plummeted by 201.72% to -$592024.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for ICCC at -$592024.0 in Q3 2025, -$125927.0 in Q2 2025, and -$329050.0 in Q1 2025.